Clinical Trial of Comparing DA-2902 and DA-2902-R in Healthy Adult Subjects

Phase 1CompletedNCT07239453

Dong-A ST Co., Ltd.40 enrolled

Overview

This study is to compare pharmacokinetics and safety profiles of DA-2902 and DA-2902-R in healthy adult subjects

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Infective Disorder

Interventions

DA-2902DRUG

single dose administration (DA-2902 one tablet once a day)

DA-2902-RDRUG

single dose administration (DA-2902-R one tablet once a day)

Eligibility

Sex: ALLMin age: 19 YearsMax age: 44 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy volunteers * BMI between 18 and 30 kg/m2 * Body weight: Male≥50kg, Female≥45kg * Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study Exclusion Criteria: * Subjects with clinically significant medical history * Subjects with history of drug abuse or addicted * Subjects with allergy or drug hypersensitivity

Locations (1)

CHA University Bundang Medical Center

Seongnam-si, Gyeonggi-do, South Korea

Outcomes

Primary Outcomes

AUCt

Time frame: pre-dose ~ 72 hr of pose-dose

Cmax

Time frame: pre-dose ~ 72 hr of post-dose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.